Supriya Lifescience Ltd
Pharmaceuticals & Biotechnology | Small Cap
Supriya Lifescience Ltd demonstrates a strong financial standing, particularly in solvency, growth, coverage, and profitability. The company efficiently manages its debt and showcases impressive growth in revenue, operating profit, and earnings per share. Its ability to cover interest and dividends is also remarkable. Profitability metrics, including gross profit margin, return on capital employed, and return on assets, reflect solid performance. However, efficiency ratios indicate potential challenges in fixed asset, inventory, and capital turnover. While liquidity is generally healthy, there's room to optimize cash management. Overall, Supriya Lifescience exhibits a robust and promising financial profile, balanced by the need for improved asset utilization.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Overvalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio4.40
- Profitability Ratio10.00
- Efficiency Ratio3.33
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio9.18
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBearish
- 4 HoursNeutral
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Supriya Lifescience Ltd demonstrates a strong financial standing, particularly in solvency, growth, coverage, and profitability. The company efficiently manages its debt and showcases impressive growth in revenue, operating profit, and earnings per share. Its ability to cover interest and dividends is also remarkable. Profitability metrics, including gross profit margin, return on capital employed, and return on assets, reflect solid performance. However, efficiency ratios indicate potential challenges in fixed asset, inventory, and capital turnover. While liquidity is generally healthy, there's room to optimize cash management. Overall, Supriya Lifescience exhibits a robust and promising financial profile, balanced by the need for improved asset utilization.
Overall Valuation Score
P/E RATIO (TTM)
35.88
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
35.88
P/B RATIO
6.26
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
8.97
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
3.26
EV/EBITDA RATIO
24.12
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹932.2 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates excellent growth across various metrics, including revenue, operating profit, earnings per share, assets, and net income. This consistent growth indicates strong market performance and effective management strategies. This growth indicates the company is doing well.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 35.55 | -13.02 | 23.64 | 22.11 | 18.97 |
| Operating Profit Growth Rate | 23.7 | -39.72 | 36.43 | 48.3 | 12.64 |
| Earnings Per Share (EPS) Growth | 11.66 | -40.77 | 32.5 | 57.77 | 11.26 |
| Asset Growth Rate | 65.17 | 11.56 | 12.32 | 20.74 | 22.03 |
| Net Income Growth Rate | 22.58 | -40.79 | 32.22 | 57.98 | 11.17 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. Adjusted and cash earnings per share are at an average level, reflecting reasonable profitability per share. Book value per share also indicates a moderate level of shareholder equity. However, dividend per share is low, and capital expenditures are high, suggesting that the company is investing heavily in its operations rather than distributing profits to shareholders. This heavy investing for operation can be risky.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 19 | 11.25 | 14.88 | 23.5 | 26.12 |
| Cash Earnings Per Share (Cash EPS) | 20.25 | 12.75 | 16.88 | 26 | 29.62 |
| Book Value Per Share | 77 | 87.38 | 101.88 | 124.62 | 149.75 |
| Dividend Per Share (DPS) | 0.57 | 0.56 | 0.74 | 0.93 | 1.04 |
| Capital Expenditures (CapEx) | 60 | 108 | 146 | 162 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits excellent profitability ratios, including gross profit margin, return on capital employed, return on equity, return on assets, operating margin, and net margin. This consistently high profitability indicates effective cost management, efficient asset utilization, and strong overall financial performance. This reflects effective management and strong financial health.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 38.49 | 25.38 | 28.07 | 34.63 | 32.13 |
| Return on Capital Employed (ROCE) | 43 | 19 | 22 | 27 | 25 |
| Return on Equity (ROE) | 24.68 | 12.88 | 14.6 | 18.86 | 17.45 |
| Return on Assets (ROA) | 29.12 | 15.73 | 19.11 | 23.47 | 21.67 |
| Operating Margin | 40.38 | 27.98 | 30.88 | 37.5 | 35.51 |
| Net Margin | 28.68 | 19.52 | 20.88 | 27.01 | 25.24 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios suggest some challenges in asset utilization. While the receivables turnover is average, the fixed asset turnover and capital turnover are lower than ideal, indicating potential inefficiencies in generating revenue from fixed assets and overall capital. High days sales in inventory also suggest slow-moving inventory, which could tie up working capital.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.79 | 1.76 | 1.84 | 1.54 | 1.2 |
| Inventory Turnover Ratio | 3.98 | 3.31 | 4.08 | 4.49 | 4.04 |
| Receivables Turnover Ratio | 5.61 | 4.61 | 5.79 | 5.66 | 4.69 |
| Days Sales in Inventory Ratio | 91.71 | 110.27 | 89.46 | 81.29 | 90.35 |
| Receivable Days | 65.06 | 79.18 | 63.04 | 64.49 | 77.83 |
| Capital Turnover Ratio | 0.85 | 0.65 | 0.69 | 0.69 | 0.69 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company demonstrates excellent coverage ratios, indicating a strong ability to meet its interest and dividend obligations. High interest coverage suggests the company can easily pay its interest expenses, while strong equity dividend coverage shows it can comfortably meet its dividend payments. This indicates a strong level of financial security.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 52.75 | 42 | 34.2 | 125 | 138.5 |
| Equity Dividend Coverage Ratio | 33.33 | 20 | 20 | 25 | 25 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits excellent solvency, indicating a very low level of debt relative to its equity and assets. This conservative capital structure suggests minimal financial risk and a strong capacity to meet its long-term obligations. This provides substantial financial stability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
| Debt to Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
| Equity Ratio | 0.99 | 0.99 | 0.99 | 0.99 | 1 |
| Debt To Asset Ratio | 0.01 | 0.01 | 0.01 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is generally strong, indicating a good ability to meet its short-term obligations. The current and quick ratios demonstrate sufficient liquid assets. However, the cash ratio indicates a moderate level of immediately available cash, and the operating cash flow ratio suggests that the company generates a reasonable amount of cash from its operations. A higher cash ratio would provide more financial flexibility.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 4.43 | 4.07 | 3.95 | 4.07 | 3.47 |
| Quick Ratio | 3.62 | 3.05 | 3.11 | 3 | 2.43 |
| Cash Ratio | 2.01 | 1.38 | 0.74 | 0.72 | 0.51 |
| Operating Cash Flow Ratio | 0.43 | 0.56 | 1.12 | 1.5 | 0 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 22.52 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 35.90 | Neutral | 369.00 | 19.44 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.30 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 28.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Shilpa Medicare Ltd | 5.94 | 44.32 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 18.41 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 31.22 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 17 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 20 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 21 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
| 22 | Procter & Gamble Health Ltd | 3.45 | 31.71 | Neutral | 457.00 | 196.94 | 327.00 |
The management of Supriya Lifescience presents a mixed performance. Strong profit growth and a high promoter holding are positive indicators. However, fluctuating sales growth and high inventory days raise concerns. The company demonstrates good capital efficiency but needs to address inconsistencies in revenue expansion and working capital management to enhance overall performance.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Strong Profit Growth | 58% | Excellent profit growth |
| High Promoter Holding | 68.30% | Indicates confidence and alignment | |
| Good ROCE | 27% | Capital is being used productively | |
| CONS | Fluctuating Sales Growth | -13.04% to 35.49% | Inconsistent revenue expansion |
| High Inventory Days | 205 | Operational inefficiencies in working capital management |
Financial Performance & Growth
Supriya Lifescience's financial performance shows inconsistencies. While profit growth is positive, sales growth has varied significantly. The operating profit margin (OPM) has experienced volatility but remains generally healthy.
Sales Growth: Sales growth has varied.
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales Growth (%) | 15.86% | 30.50% | 12.17% | 25.53% | 35.49% | -13.04% | 23.74% | 22.11% |
Profit Growth: Compounded Profit Growth is 7% over 3 years and TTM is 58%.
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Profit (Rs Cr) | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 |
Capital Efficiency & Returns
Supriya Lifescience demonstrates reasonable capital efficiency. The Return on Capital Employed (ROCE) is at acceptable levels, indicating that the company is utilizing its capital effectively.
ROCE %
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| ROCE (%) | 37% | 50% | 60% | 43% | 19% | 22% | 27% |
The ROCE has decreased from a high of 60% in March 2021 to 27% in March 2025. Despite the decline, the ROCE remains within an acceptable range.
Financial Health & Prudence
Supriya Lifescience exhibits strong financial health and prudence. The company has significantly reduced its borrowings over the years.
Borrowings (Rs Cr):
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Borrowings (Rs Cr) | 140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 |
The company has substantially decreased its debt, enhancing its financial stability.
Strategic & Operational Indicators
Supriya Lifescience faces challenges in its strategic and operational indicators, particularly in working capital management. Inventory days are high, indicating potential inefficiencies.
Inventory Days:
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 |
High inventory days suggest that the company might be facing challenges in efficiently managing its stock.
The risk assessment for Supriya Lifescience indicates a moderate level of risk due to the absence of specific data on key evaluation areas. The absence of data makes it difficult to fully assess the company's risk exposure. A balanced approach to risk management is necessary to address the identified vulnerabilities effectively.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10933.50Bearish
- SMA 20931.76Bullish
- SMA 50949.06Bearish
- EMA 10933.34Bearish
- EMA 20935.46Bearish
- EMA 50940.79Bearish
- DEMA 10932.77Bearish
- DEMA 20929.67Bullish
- DEMA 50942.77Bearish
- TEMA 10934.17Bearish
- TEMA 20930.83Bullish
- TEMA 50923.95Bullish
- MACD-3.77Bullish
- ADX15.56Weak Trend
- IndicatorValueSignal
- RSI45.56Neutral
- CCI12.61Neutral
- ROC 90.34Bullish
- ROC 141.74Bullish
- ROC 25-0.92Bearish
- Stoch K56.15Neutral
- Stoch D60.16Neutral
- IndicatorValueSignal
- BB Upper946.54Neutral
- BB Middle931.75Neutral
- BB Lower916.97Neutral
- ATR10.82Low Volatility
- IndicatorValueSignal
- MFI71.81Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10929.70Bullish
- SMA 20939.96Bearish
- SMA 50946.94Bearish
- EMA 10934.20Bearish
- EMA 20938.59Bearish
- EMA 50929.36Bullish
- DEMA 10930.49Bullish
- DEMA 20932.54Bearish
- DEMA 50967.48Bearish
- TEMA 10932.59Bearish
- TEMA 20925.10Bullish
- TEMA 50945.29Bearish
- MACD-4.60Bearish
- ADX23.36Weak Trend
- IndicatorValueSignal
- RSI46.31Neutral
- CCI-45.58Neutral
- ROC 92.09Bullish
- ROC 14-0.77Bearish
- ROC 25-0.43Bearish
- Stoch K45.83Neutral
- Stoch D44.34Neutral
- IndicatorValueSignal
- BB Upper967.85Neutral
- BB Middle939.96Neutral
- BB Lower912.06Neutral
- ATR16.70Low Volatility
- IndicatorValueSignal
- MFI50.70Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10937.81Bearish
- SMA 20947.59Bearish
- SMA 50874.64Bullish
- EMA 10937.04Bearish
- EMA 20934.77Bearish
- EMA 50880.80Bullish
- DEMA 10931.04Bullish
- DEMA 20954.46Bearish
- DEMA 50976.17Bearish
- TEMA 10924.53Bullish
- TEMA 20931.45Bullish
- TEMA 50N/AN/A
- MACD11.37Bearish
- ADX33.53Strong Trend
- IndicatorValueSignal
- RSI51.91Neutral
- CCI-76.67Neutral
- ROC 9-3.27Bearish
- ROC 14-4.41Bearish
- ROC 254.07Bullish
- Stoch K23.65Neutral
- Stoch D20.89Neutral
- IndicatorValueSignal
- BB Upper986.79Neutral
- BB Middle947.59Neutral
- BB Lower908.39Neutral
- ATR29.84Low Volatility
- IndicatorValueSignal
- MFI34.69Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10944.52Bearish
- SMA 20904.95Bullish
- SMA 50764.68Bullish
- SMA 100703.82Bullish
- SMA 200717.13Bullish
- EMA 10932.71Bearish
- EMA 20895.46Bullish
- EMA 50804.25Bullish
- EMA 100750.53Bullish
- EMA 200719.80Bullish
- DEMA 10955.38Bearish
- DEMA 20973.40Bearish
- DEMA 50900.42Bullish
- DEMA 100805.43Bullish
- DEMA 200764.39Bullish
- TEMA 10935.30Bearish
- TEMA 20977.69Bearish
- TEMA 50968.95Bearish
- TEMA 100860.63Bullish
- TEMA 200766.07Bullish
- MACD55.11Bearish
- ADX45.20Strong Trend
- IndicatorValueSignal
- RSI58.48Neutral
- CCI25.58Neutral
- ROC 14-3.76Bearish
- ROC 2536.32Bullish
- Stoch K35.81Neutral
- Stoch D47.65Neutral
- IndicatorValueSignal
- BB Upper1070.97Neutral
- BB Middle904.95Neutral
- BB Lower738.93Neutral
- ATR50.97Low Volatility
- IndicatorValueSignal
- MFI64.64Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20700.96Bullish
- SMA 50711.27Bullish
- EMA 20752.47Bullish
- EMA 50710.24Bullish
- DEMA 20809.31Bullish
- DEMA 50763.24Bullish
- TEMA 20865.70Bullish
- TEMA 50754.72Bullish
- MACD53.57Bullish
- ADX27.85Strong Trend
- IndicatorValueSignal
- RSI71.20Overbought
- CCI302.65Overbought
- ROC 1455.62Bullish
- ROC 2532.43Bullish
- Stoch K84.87Overbought
- Stoch D87.76Overbought
- IndicatorValueSignal
- BB Upper940.06Overbought
- BB Middle700.96Neutral
- BB Lower461.85Neutral
- ATR78.69High Volatility
- IndicatorValueSignal
- MFI82.18Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6718.01Bullish
- SMA 12715.38Bullish
- SMA 24668.32Bullish
- EMA 6754.96Bullish
- EMA 12716.72Bullish
- EMA 24651.03Bullish
- DEMA 6804.52Bullish
- DEMA 12776.82Bullish
- DEMA 24790.47Bullish
- TEMA 6842.79Bullish
- TEMA 12773.86Bullish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX34.69Strong Trend
- IndicatorValueSignal
- RSI61.83Neutral
- CCI139.18Overbought
- ROC 25144.22Bullish
- ROC 5096.37Bullish
- Stoch K73.97Neutral
- Stoch D77.96Neutral
- IndicatorValueSignal
- BB Upper872.89Overbought
- BB Middle707.23Neutral
- BB Lower541.57Neutral
- ATR129.43High Volatility
- IndicatorValueSignal
- MFI66.82Neutral